Attovia Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Attovia Therapeutics, Inc. - overview
Established
2023
Location
San Carlos, CA, US
Primary Industry
Biotechnology
About
Founded in 2023 and based in California, US, Attovia Therapeutics, Inc. operates as a biotechnology company that develops biotherapeutics for the treatment of immune-mediated disease and cancer. Attovia is focused on creating a pipeline of biotherapeutics in immune-mediated disease and oncology. The company leverages Attobody™, Alamar Biosciences’ novel biparatopic nanobody platform, to generate small format binders with low picomolar affinity, enhanced specificity, accelerated internalization, and fast tissue penetration.
Attovia’s lead program is an Attobody to treat immune disease. The company is currently progressing multiple programs and plans to initiate additional discovery projects. The company will use the funding to support the development of its platform called Attobody and its clinical concept.
Current Investors
Frazier Healthcare Partners, VenBio, Illumina Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.attovia.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.